Cavitation of lesions is common in non-squamous non-small cell lung cancer (non-squamous-NSCLC) patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFRIs). However, traditional response evaluation criteria in solid tumors (RECIST) do not take cavitation into consideration and may no longer be accurate for potentially reflecting the real clinical efficacy of anti-vessel growth therapy. Here, we aimed to optimize the traditional RECIST version 1.1 by adding cavitation into the evaluation criteria.

中文翻译：

---

修改后的实体瘤疗效评估标准：贝伐珠单抗治疗后非鳞状非小细胞肺癌患者更好的疗效评估标准

病变空化在接受血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFRI）治疗的非鳞状非小细胞肺癌（非鳞状非小细胞肺癌）患者中很常见。然而，传统的实体瘤疗效评估标准（RECIST）没有考虑空化现象，可能不再准确地反映抗血管生长治疗的真实临床疗效。在这里，我们的目标是通过在评估标准中添加空化来优化传统的 RECIST 1.1 版。